| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1464-5491.2005.01726.X |
| P698 | PubMed publication ID | 16409565 |
| P2093 | author name string | Home PD | |
| Ashwell SG | |||
| Gebbie J | |||
| P2860 | cites work | Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study | Q44286389 |
| P433 | issue | 1 | |
| P921 | main subject | preproinsulin | Q7240673 |
| type-1 diabetes | Q124407 | ||
| insulin glargine | Q417317 | ||
| P304 | page(s) | 46-52 | |
| P577 | publication date | 2006-01-01 | |
| P1433 | published in | Diabetic Medicine | Q15758639 |
| P1476 | title | Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times | |
| P478 | volume | 23 |
| Q50993128 | A randomized pilot study in Type 1 diabetes complicated by severe hypoglycaemia, comparing rigorous hypoglycaemia avoidance with insulin analogue therapy, CSII or education alone. |
| Q34436383 | A review of the pharmacological properties of insulin degludec and their clinical relevance |
| Q38136581 | Basal insulin analogues in the management of diabetes mellitus: What progress have we made? |
| Q100472612 | Circadian Variation in Efficacy of Medications |
| Q34296834 | Clinical Experience with Insulin Glargine in Type 1 Diabetes |
| Q79603587 | Comment on: Distiller LA, Joffe BI (2006) From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? Diabetologia 49:2793- |
| Q37022851 | Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT). |
| Q38692387 | Insulin analogues in type 1 diabetes mellitus: getting better all the time |
| Q49174475 | Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes |
| Q36521871 | Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus |
| Q34449820 | Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. |
| Q36920613 | Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilised? |
| Q27015047 | Modern basal insulin analogs: An incomplete story |
| Q46963862 | Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellit |
| Q37242616 | New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations |
| Q36898852 | Refining basal insulin therapy: what have we learned in the age of analogues? |
| Q26999454 | The evolution of insulin glargine and its continuing contribution to diabetes care |
| Q46452341 | The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. |
Search more.